Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2597-2607

  Brixner, Diana I ^a   Jackson II, Kenneth C ^b   Sheng, Xiaoming ^c   Nelson, Richard E ^a   Keskinaslan, Abdulkadir ^d  

^a UNIVERSITY OF UTAH   (United States)

^b PACIFIC UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adherence; Fixed dose combination; Hydrochlorothiazide; Hypertension; Medical costs; Persistence; Prescription costs; Valsartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; VALSARTAN;

ADD ON THERAPY; ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COVARIANCE; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DIURETICS; DRUG COMBINATIONS; DRUG COSTS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TETRAZOLES; VALINE;

EID: 53349175183     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802319364     Document Type: Article

References (26)

1. Andrade SE, Gurwitz JH, Field TS, et al. Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care 2004;10:481-6
2. Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich) 2008; 10:20-6
3. Dusing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006;22:1545-53
4. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002;4:343-9
5. Chalmers J. The importance of drug combinations for effective control of hypertension. Clin Exp Hypertens. 1999;21:875-84
6. Frank J. Managing hypertension using combination therapy. Am Fam Physician 2008;77:1279-86
7. White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit 2008;13:123-9
8. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-6
9. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563-71
10. Brixner DI, Joish VN, Odera GM, et al. Effects of benefit design change across 5 disease states. Am J Manag Care 2007;13:370-6
11. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
12. Faulkner MA, Hilleman DE. Amlodipine/benazepril: fixed dose combination therapy for hypertension. Expert Opin Pharmacother 2001;2:165-78
13. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007;64:1279-83
14. Taylor AA. Combination drug treatment of hypertension: have we come full circle? Curr Cardiol Rep 2004;6:421-6
15. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003;9:324-32
16. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
17. Berger M, Bingefors K, Hedblom E, et al. Health care cost, quality, and outcomes: ISPOR Book of Terms, Ist edn. Lawrenceville, NJ: ISPOR, 2003
18. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28(9):1411-24; discussion 1410
19. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008;10:185-94
20. Brixner DI, Jackson KC, Oberg B, et al. Factors influencing compliance with combination antihypertensive pharmacotherapy in a large US database. Value Health 2007; 10:A432
21. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
22. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
23. Weir MR, Maibach EW, Bakris GL, et al. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med 2000;160:481-90
24. Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep 2000;2:510-14
25. Muszbek N, Brixner D, Benedict A, et al. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008; 62:338-51
26. Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006; 47:1039-48